Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹71.04
2.46 (3.59%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹254 Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
N/A
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹44.1+61.1%
52W High₹121.44-41.5%
Current Price
₹71.04
Circuit Limits (5%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹67.49
Upper Circuit₹74.59
Reference Price
₹71.04
Investment Checklist
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹78.83
Bull Flag on 1D — target ₹74.97
EMA(9) Crossover: Price crossed above EMA(9): Fresh bullish momentum signal.
EMA(20) Crossover: Price crossed above EMA(20): Fresh bullish momentum signal.
SuperTrend(10,3): Price above SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
43%
Trend
NEUTRAL
NEUTRAL
Mixed MA signals — sideways/transition
EMA20
69.64
EMA50
66.32
EMA200
74.84
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows4
Lower Highs3
Lower Lows5
Support & Resistance Levels
Resistance (Above)
₹73.00
₹77.02
₹79.06
₹84.70
₹86.90
Support (Below)
₹67.91
₹65.81
₹64.00
₹61.99
₹61.25
Volume Analysis
TrendDECREASING
Change-28.60%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹70.33
3% Risk₹68.91
5% Risk₹67.49
7% Risk (Custom)
₹66.07Technical Levels
1x ATR (Volatility)₹66.75
2x ATR (Swing)₹62.46
3x ATR (Trend)₹58.17
Immediate Support₹67.91
Moving Averages
EMA 9 (Short-term)₹70.55
EMA 20 (Medium-term)₹69.64
EMA 50 (Trend)₹66.32
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹28.5 Cr | ₹33 Cr | ₹36.7 Cr | ₹30.7 Cr |
| Net Profit | ₹1.8 Cr | ₹93,26,000 | ₹-3.4 Cr | ₹-3,000 |
| EPS | — | ₹0.25 | ₹-0.94 | ₹0.00 |
| Operating Profit | ₹4.7 Cr | ₹4.3 Cr | ₹-1.4 Cr | ₹2.8 Cr |
ROE
7.74%
ROCE
9.32%
Debt/Equity
0.37
Current Ratio
1.45
OPM
9.15%
NPM
-0.00%
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Lyka Labs Limited | ₹71.04 | +3.59% | — | ₹254 Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 01 Aug 2024 | Annual General Meeting | AGM |
| 21 Jul 2023 | Annual General Meeting | AGM |
| 21 Jul 2022 | Annual General Meeting | AGM |
| 22 Jul 2021 | Annual General Meeting | AGM |
| 16 Sept 2020 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for LYKALABS
View AllNEWS
negative
Business Standard - Markets 46d ago
Lyka Labs reports consolidated net loss of Rs 7.61 crore in the March 2026 quarter
Sales decline 16.15% to Rs 28.03 crore
LYKALABSHealthcare
negative
ET Markets - Industry 52d ago
NCLAT allows Lyka Labs appeal; asks Modi Lifecare to pay Rs 63 lakh or face insolvency proceedings
The NCLAT has ruled in favor of Lyka Labs. It overturned a previous NCLT decision. Modi Lifecare Industries must now pay Rs 63 lakh within 30 days. Failure to pay will lead to insolvency proceedings against the company. The tribunal found that Modi Lifecare acknowledged its debt. This ruling stems from unpaid royalties under a technical guidance agreement.
LYKALABSHealthcare